ReviewCurrent hypertension reports2022
High Prevalence of Autonomous Aldosterone Production in Hypertension: How to Identify and Treat It.
Review in Current hypertension reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- The prevalence of metabolic syndrome in primary aldosteronism and essential hypertension: A systematic review and meta-analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2024Pooled it
- Predictive factors of clinical success after adrenalectomy in primary aldosteronism: A systematic review and meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Potential under-recognition of primary aldosteronism in young adults with hypertension.Journal of human hypertension · 2026Article
- Performance of Primary Aldosteronism Screening Tests Before Washout of Dihydropyridine Calcium Channel Blockers: An Exploratory Retrospective Study.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Aldosterone fuels the progression of cardiovascular-kidney -metabolic syndrome: focus on primary aldosteronism spectrum.Endocrine · 2026Review
- Overcoming variable response in renal denervation: Key strategies for reliable clinical implementation.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies.International journal of hypertension · 2026Review
- Cosyntropin-Stimulated Aldosterone Reserve of the Nondominant Adrenal Predicts Surgical Outcomes in Primary Aldosteronism.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Resolution of paradoxical bilateral aldosterone suppression with mass spectrometry.European journal of endocrinology · 2025Article
- Performance of Aldosterone-to-renin Ratio Before Washout of Antihypertensive Drugs in Screening of Primary Aldosteronism.The Journal of clinical endocrinology and metabolism · 2024Article
- Evaluation of a Best-Practice Advisory for Primary Aldosteronism Screening.JAMA internal medicine · 2024Article
- Comparison of saline infusion test and captopril challenge test in the diagnosis of Chinese with primary aldosteronism in different age groups.Frontiers in endocrinology · 2024Observational
- Primary aldosteronism: molecular medicine meets public health.Nature reviews. Nephrology · 2023Review
- The Entity of Connshing Syndrome: Primary Aldosteronism with Autonomous Cortisol Secretion.Diagnostics (Basel, Switzerland) · 2022Review
- Primary aldosteronism - a multidimensional syndrome.Nature reviews. Endocrinology · 2022Review
- Lateralization inEndocrinology, diabetes & metabolism · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
purpose of reviewPrimary aldosteronism (PA) affects millions of individuals worldwide. When unrecognized, PA leads to cardiovascular and renal complications via mechanisms independent from those mediated by hypertension. In this review, we emphasize the importance of PA screening in at-risk populations, and we provide options for customized PA therapy, with consideration for a variety of clinical care settings. RECENT
findingsCompelling evidence puts PA at the forefront of secondary hypertension etiologies. Cardiovascular and renal damage likely begins in early stages of renin-independent aldosterone excess. PA must be considered not only in patients with resistant hypertension or hypokalemia, but also when hypertension is associated with obstructive sleep apnea or atrial fibrillation, or in those with early-onset hypertension. Screening with plasma aldosterone and renin is widely accessible, and targeted PA therapy can successfully circumvent the excess cardiorenal risk relative to equivalent primary hypertension. Identifying and treating PA in early stages provide opportunities for personalized hypertension therapy in a large number of patients. Additionally, early targeted therapy of PA is essential for pivoting the care of such patients from reactive to preventive of cardiovascular and renal morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.